Monoclonal antibody BR55-2
Latest Information Update: 17 Nov 2003
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 17 Nov 2003 Discontinued - Phase-I for Breast cancer in USA (IV)
- 11 Mar 2002 No development reported - Phase-I for Breast cancer in USA (IV)
- 23 Mar 1995 Phase-I clinical trials for Breast cancer in USA (IV)